Compare Heron Therapeutics Inc (HRTX) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MGM Resorts International — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while MGM Resorts International trades at $46.57 (market cap $11.86B). The key difference: MGM Resorts International is far larger — about 129.7× Heron Therapeutics Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MGM | |
|---|---|---|
Market Cap | $91.46M | $11.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $50.69 |
52-Week Low | $0.39 | $30.72 |
Enterprise Value | $189.36M | $40.90B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.48, up 2.06% today, with a bullish technical signal but mixed earnings performance. The company reported Q1 2026 revenue of $151M but missed EPS estimates with a $0.04 loss. Despite negative net income margins, analyst consensus remains overwhelmingly bullish with 18 buy ratings. Recent patent litigation developments and seasonal pressures have impacted quarterly results.
Outlook remains challenged by ongoing losses and competitive pressures, though strong analyst support suggests potential upside if execution improves. Key risks include patent litigation outcomes, cash flow sustainability, and ability to achieve profitability. The stock's low price presents speculative opportunity but requires careful risk management.
MGM trades at $45.67, down 1.0% today, with a neutral technical stance and mixed earnings history. The company reported $17.54B revenue in 2025 but net income fell to $206M, with profit margins narrowing. Recent news highlights acquisition interest from Barry Diller at $48.30 per share, creating investor uncertainty. Cash flow trends show improving operational strength, though net cash flow remains negative.
Outlook is balanced: potential upside exists from the acquisition offer and steady revenue, but risks include declining profitability and high debt. Analysts are split evenly between Buy and Hold, with a $48.93 consensus target suggesting modest upside. Investors should weigh takeover prospects against fundamental pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
